PLx Pharma Inc.
PLx Pharma Inc. (PLXP) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
plxp · pe ratio · data through Dec 31, 2021
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for PLx Pharma Inc. (PLXP) measures how much investors pay for each dollar of the company's trailing earnings. PLXP's current PE ratio of N/A is calculated by dividing its stock price of $0.09 by its TTM earnings per share of -$2.18.
Source: FMP · /ratios-ttm · /analyst-estimates · 2021-12-31
PE Ratio History
2012 – 2021 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
PLx Pharma Inc.You PLXP | $3M | N/A | — | -$2.18 |
 Applied DNA Sciences, Inc. APDN | $7M | N/A | — | -$134.23 |
 Athenex, Inc. ATNX | $2M | N/A | — | -$15.13 |
 Aspira Women's Health Inc. AWH | $2M | N/A | — | -$0.37 |
 Biophytis S.A. BPTS | $3M | N/A | — | -$12.55 |
 Eiger BioPharmaceuticals, Inc. EIGRQ | $13M | N/A | — | -$50.78 |
 Vyome Holdings, Inc. HIND | $13M | N/A | — | -$4.75 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2021-12-31Latest FY2021 | — | $-2.18 | — | |
2020-12-31 FY2020 | — | $-1.55 | — | |
2019-12-31 FY2019 | — | $-2.39 | — | |
2018-12-31 FY2018 | 14.90x | $0.10 | — | |
2017-12-31 FY2017 | — | $-2.19 | — | |
2016-12-31 FY2016 | — | $-16.45 | — | |
2015-12-31 FY2015 | — | $-15.90 | — | |
2014-12-31 FY2014 | — | $-13.84 | — | |
2013-12-31 FY2013 | — | $-6.94 | — | |
2012-12-31 FY2012 | — | $-3.64 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for PLx Pharma Inc. (PLXP) measures how much investors pay for each dollar of the company's trailing earnings. PLXP's current PE ratio of N/A is calculated by dividing its stock price of $0.09 by its TTM earnings per share of -$2.18.
Frequently asked questions
PLXP pe ratio · 6 questionsPLXP's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.09 and TTM EPS of -$2.18. Data sourced from Financial Modeling Prep via PLXP's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · PLx Pharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09